| STAGE |
Modality Treatment |
TNM |
Stage |
Lost to follow up |
|
|
N
|
T1
|
T2
|
T3
|
T4
|
T 1-4
|
N 1-3
|
M1
|
|
| Organ confined T1-T2 N0M0 n=415 |
Radical Prostatectomy RRP 81 PRP 4Laparoscopic 7 |
92 |
17 |
75 |
|
|
|
|
|
6 |
| Brachytherapy |
70 |
23 |
47 |
|
|
|
|
|
9 |
| EBRT |
155 |
24 |
131 |
|
|
|
|
|
18 |
| Hormonal/ Chemotherapy |
98 |
24 |
74 |
|
|
|
|
|
14 |
| Locally advanced T3-T4 M0 n=167 |
Androgen Deprivation Neoadjuvant |
167 |
|
|
|
|
|
|
|
16 |
| Brachytherapy |
3 |
- |
- |
3 |
|
|
|
|
-
|
| EBRT |
64 |
|
|
57 |
7 |
|
|
|
(7) |
| Hormonal therapy |
100 |
|
|
40 |
60 |
|
|
|
(9) |
| Advanced metastatic T1-4 N1-3 M1 n=87 |
Hormonal androgen deprivation therapy |
87 |
|
|
|
|
|
87 |
|
8 |
|
Total |
669 |
88 |
327 |
100 |
67 |
|
87 |
|
71 |
| RRP (Radical Retropubic Prostatectomy), PRP (Perineal Radical Prostatectomy)Lost to follow up (71/669) 10.6%, Mortality in 8 years in advanced and metastatic cases were 91/669 (13.6%) due to bleeding 2(0.3%), obstructive uropathy 20(3%), urosepsis 20 (3%), paraplegia 31(4.6%) and sepsis 18 (2.7%). |
